(Q37811516)

23 August 2017

title

Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease (English)

1 reference

23 August 2017

Impact of Mammalian Target of Rapamycin Inhibition on Autosomal-Dominant Polycystic Kidney Disease (English)

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.07.008

autosomal dominant polycystic kidney disease

1 September 2024

main subject

0 references

1 reference

2

A. D. Kistler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21095452

1 September 2024

author name string

R. P. Wüthrich

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21095452

1 September 2024

A. L. Serra

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21095452

1 September 2024

language of work or name

English

0 references

publication date

1 November 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0041134510010535?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.07.008

https://api.elsevier.com/content/article/PII:S0041134510010535?httpAccept=text/plain

1 September 2024

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2010.07.008

Transplantation Proceedings

1 September 2024

published in

1 reference

23 August 2017

volume

42

1 reference

23 August 2017

issue

9 Suppl

1 reference

23 August 2017

page(s)

S44-6

1 reference

Autosomal dominant polycystic kidney disease

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Autosomal dominant polycystic kidney disease: the last 3 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Sirolimus reduces polycystic liver volume in ADPKD patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Volume progression in polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.008

7 January 2021

Identifiers

1 reference

23 August 2017

1 reference